The Diligent Observer Podcast
🗞️ Get essential angel intel straight to your inbox every week with The Diligent Observer Newsletter [https://www.thediligentobserver.com/]. 🗞️ Today's episode explores three ideas that caught my attention: ① Disciplined screening can be tested: Yaniv and Alex explain how Mid Atlantic Bio Angels reviewed more than a decade of life science startup applications to ask whether the group’s screening criteria were helping or causing them to miss the winners. ② Life science angel investing has different economics: In therapeutics, medical devices, diagnostics, and digital health, the capital path matters. A company may be promising, but if it needs too much money before reaching an exit, it may be a better fit for venture capital than angel capital. ③ Angel-scale life science exits are about being acquired early: Alex explains why time, capital intensity, clinical risk, and later-stage dilution can make “growing big” less attractive for early angel investors than reaching a strategic acquisition sooner. Yaniv is a co-founder of Mid Atlantic Bio Angels and a biotech CEO. Alex is an oncology commercialization professional who helped lead a detailed analysis of BioAngels’ screening criteria, applicant outcomes, missed deals, and exit patterns. During our conversation, he shares: • Why BioAngels invests in fewer than 1.5% of companies that apply. • What they learned by analyzing nearly 1,100 life science startup applications. • Why only a small percentage of passed companies reached an exit. • How life science angels think about dilution, time to exit, and capital requirements. • Why one of their first screening questions is: how much money do you need to reach an exit? • Why some companies are better VC opportunities than angel investment opportunities. Connect with Yaniv: Yaniv's LinkedIn [https://www.linkedin.com/in/yaniv-sneor-5534131/] Connect with Alex: Alex's LinkedIn [https://www.linkedin.com/in/alexpederson/] Connect with Andrew: Newsletter [https://www.thediligentobserver.com/] | X [https://twitter.com/akazlow] | LinkedIn [https://www.linkedin.com/in/andrewkazlow] | Book [https://angelops.pitchfact.com/] | Website [https://pitchfact.com/] Stuff We Reference: Mid Atlantic Bio Angels [https://bioangels.net/]BioAngels Investment Criteria [https://bioangels.net/investment-criteria/]BioAngels Investment Process [https://bioangels.net/investment-process/]ACA Data Insight: “What Do Outcomes Teach Us About Screening Criteria?” [https://angelcapitalassociation.org/blog/what-do-outcomes-teach-us-about-screening-criteria/]ACA Data Insight: “IPOs as Outcomes for Life Science Angels: What Changes, and When?” [https://angelcapitalassociation.org/blog/ipos-as-outcomes-for-life-science-angels-what-changes-and-when/]Angel Capital Association [https://angelcapitalassociation.org/] PitchBook [https://pitchbook.com/]ClinicalTrials.gov [https://clinicaltrials.gov/]MedTech Strategist [https://www.medtechstrategist.com/]BioSpace Denatured episode with Yaniv Sneor and Alex Pederson [https://www.biospace.com/business/what-makes-life-science-angel-investment-work] Know someone who would enjoy this episode? Share it with them! All opinions expressed are personal and may not reflect the views of the individual’s organization or of The Diligent Observer. Not investment advice. Want more? * Get essential angel intel straight to your inbox every week with The Diligent Observer Newsletter [https://thediligentobserver.com/]. * Check out the entire show library [https://podcast.thediligentobserver.com/] and follow via Apple Podcasts [https://podcasts.apple.com/us/podcast/the-diligent-observer-podcast/id1759589362], Spotify [https://open.spotify.com/show/2c7mLtTDy3hdWMnCWh9a9l], and YouTube [https://www.youtube.com/playlist?list=PLLEI-yh8KE6MTx4PFYE3SVCCl5lmcojwO]. All opinions are personal and may not reflect the views of The Diligent Observer. Not investment advice.
74 jaksot
Kommentit
0Ole ensimmäinen kommentoija
Rekisteröidy nyt ja liity The Diligent Observer Podcast-yhteisöön!